

CIN: L24230TG1993PLC015426
An ISO 9001:2015 & WHO GMP Certified Company

Corporate Office: # 1st Floor, Lakeview Plaza, Plot No.127 & 128, Amar Co-operative Society, Opp. Madhapur Police Station Road, Near Durgam Cheruvu, Madhapur, Hyderabad - 500 033.

Tel: 040-40040783

Dated: 14.06.2021

Ref. EOL/SEC/COMP/015/2020-21

To,
Corporate Relationship Department,
Bombay Stock Exchange Limited.
P. J. Towers, Dalal Street Fort
Mumbai - 400001

Dear Sir,

Subject: Results Press Release for the quarter ended 31.03.2021:

**Scrip Code: 524790** 

With reference to the captioned subject, please find enclosed the Press Release duly issued by the Company on the Financial Results for the fourth Quarter and financial year ended March 31, 2021.

Please bring the aforesaid press release to the notice of the members of the exchange and the investors at large.

Thanking You,

Yours' Faithfully For Everest Organics Limited

Rekha Singh Company Secretary

Encl: As above



CIN: L24230TG1993PLC015426
An ISO 9001:2015 & WHO GMP Certified Company

Corporate Office: # 1st Floor, Lakeview Plaza, Plot No.127 & 128, Amar Co-operative Society, Opp. Madhapur Police Station Road, Near Durgam Cheruvu, Madhapur, Hyderabad - 500 033.

Tel: 040-40040783

## Hyderabad – India, June 14, 2021

**Result Press Release** 

# Impressive Year for Everest Organics Limited Stable Revenue and PAT growth YoY Dividend @ 10%

## Revenue Growth 8.58%, PAT growth of 25.89%

Hyderabad, June 14, 2021: **Everest Organics Limited** today announced its audited financial results for the fourth quarter and financial year ended March 31, 2021 ("Q4 & FY 2020-21"). Another sturdy and progressive year for the Company.

#### Q4 & FY2020-21 RESULT HIGHLIGHTS

### Highlights for the FY 2020-21 (Y-o-Y)

- > Income from Operations ("Revenue") was INR 181.56 Cr as compared to INR 167.21 Cr in the previous year, registering 8.58% growth in revenue.
- Profit after Taxes and Minority Interest ("PAT") was INR 13.71 Cr as compared to INR 10.89 Cr in the previous year registering 25.89% growth in PAT.
- ➤ EPS was INR 17.14/- as compared to INR 13.62/- in the previous year, registering 25.84% growth in earning per share.

## Key growth highlights in past 3 year:

Rs. In Crores

Particulars	FY 2018-19	FY 2019-20	FY 2020-21	CAGR
Total Income	156.39	168.66	182.62	5.30
PBT	12.32	14.09	17.27	22.36
PAT	7.50	10.89	13.71	22.27
EPS	9.39	13.62	17.14	22.21



CIN: L24230TG1993PLC015426
An ISO 9001:2015 & WHO GMP Certified Company

Corporate Office: # 1st Floor, Lakeview Plaza, Plot No.127 & 128, Amar Co-operative Society, Opp. Madhapur Police Station Road, Near Durgam Cheruvu, Madhapur, Hyderabad - 500 033.

Tel: 040-40040783





## **Highlights for the Fourth Quarter (Q-o-Q)**

- > Income from Operations ("Revenue") was INR 45.04 Cr as compared to INR 46.29 Cr in the previous year; vide spread lockdown globally had a marginal impact in the revenue growth.
- Profit after Taxes and Minority Interest ("PAT") was INR 2.20 Cr as compared to INR 3.96 Cr in the previous year, due to closure order it had a marginal impact in PAT for the quarter.
- ➤ Company has recommended a dividend @ 10% apart from Interim Dividend of 5% declared and paid, hence total dividend for the FY 2020-21 is 15%.

Commenting on the results, **Dr. Srikakarlapudi Srihari Raju, Managing Director**, Everest Organics Limited said, "We are pleased to have ended the fiscal year with steady growth across our key business in a dynamic environment affected by the pandemic. Both the top line and bottom line were affected in Q4 as result of the closure order issued by TSPCB. However, we would wish to inform that the Company has complied with all the observations as raised by the TSPCB and has already approved revocation order. We would once again reiterate that the management of EOL is fully committed to comply with all the pollutions norms, in fact the Company has undertaken more investment during the year to enhance the systems for treating the waste and be future ready for any further tightening of pollution issues. Further we continued to grow across all our businesses, enhance productivity and strengthen our development pipeline We made good progress on our pipeline efforts to focus more on **API's in anti-viral segment** (Covid related) and successfully developed "Posaconazole" an anti-fungal API and reached important milestones in the journey during the year. We look forward to execute on our key growth pillars and drive.



## CIN: L24230TG1993PLC015426 An ISO 9001:2015 & WHO GMP Certified Company

Corporate Office: # 1st Floor, Lakeview Plaza, Plot No.127 & 128, Amar Co-operative Society, Opp. Madhapur Police Station Road, Near Durgam Cheruvu, Madhapur, Hyderabad - 500 033.

Tel: 040-40040783

#### **NEW PRODUCTS LAUNCHES**

During this Financial Year the Company has successfully developed product in anti-viral segment and has commercialized the same. Moreover the management used these segments as a long term product portfolio beyond Covid-19. The Company's ability as a R&D derived organization had been strengthening with launch of Posaconazole in short span of time.

- (i) Oseltamivir: An antiviral API was launched and has been ramped up to meet the immense demand due to surge of the COVID cases in India.
- (ii) Remdevisir: Another antiviral API was launched and has been commercialized during the year.
- (iii) Posaconazole: An anti-fungal API was launched very recently and is in the advance stage commercialization.

#### **UPCOMING PRODUCTS**

We are working for the development of more products and we have in pipeline the following products:

- (i) Aprepitant: An anti-emetic API; and
- (ii) Ezetimibe: An anti-cholesterol.

#### **About Everest Organics Limited: Scrip Code: 524790**

Everest Organics Limited is a fast growing API and Bulk drug manufacturing company with world class facility and is committed to manufacturing excellent quality products and customer service. The Company produces Active Pharma Intermediates "APIs" for quality conscious customer around the globe.

Everest Organics Limited supports customers with unique value, niche products range and research driven approach.

The USFDA approved API facility in Hyderabad manufactures and exports various APIs products to more than 40 countries as well as caters to local demand in market in India.

#### **Cautionary Statement:**

Certain statements made above may be "Forward Looking" Statement within the meaning of applicable Laws & Regulations.

\*\*\*\*\*\*\*

